This review found no evidence that statins could reduce the risk of colorectal cancer. Restriction of inclusion criteria by study size for randomised trials, possible publication bias and lack of validity assessment were limitations. However, the authors' cautious conclusions appear reliable based on the evidence presented.
Risk ratios and 95% confidence intervals (CI) were calculated for each RCT on an intention-to-treat basis. For observational studies, the risk ratios from the analyses with the most adjustment for confounding factors were extracted. Some studies reported different effect sizes (odds ratios, rate ratios) but these were included in the review as risk ratios as the risk of colorectal cancer was low.
Two reviewers independently extracted the data, with disagreements resolved by consensus and referring to the original paper.
Methods of synthesis
Separate meta-analyses were performed by study design. Both fixed-effect (Mantel-Haenszel) and random-effects (DerSimonian and Laird) models were used. Statistical heterogeneity was assessed using Cochran's Q test (p<0.10 was considered significant) and the I 2 statistic. Differences in pooled results between the RCTs and observational studies were assessed using a statistical test of interaction. Subgroup analyses were performed for placebo-controlled RCTs and those of lipophilic and lipophobic statins only. Subgroup analyses of the observational studies evaluated studies published in full (not abstracts), cohort studies, and case-control studies. Publication bias was assessed using Egger's test and the Begg and Mazumdar test
